The University of Oxford and Boston Children’s Hospital are leading a $46 million Genetic Medicines Hub within the ARIA ecosystem to develop scalable antisense oligonucleotide therapies for neurodevelopmental disorders. The hub model is designed to address scale-up constraints that have historically limited delivery of RNA-targeting medicines. For founders, manufacturing partners, and clinical teams, the investment increases momentum around platform capabilities—such as reliable production, quality systems, and translational readiness—that can determine whether antisense candidates can progress beyond early proof-of-concept. The funding also places institutional emphasis on moving toward repeatable therapeutic manufacturing and clinical deployment pathways.